Boston Scientific AGENT(TM) Drug-Coated Balloon Demonstrates Superiority to Uncoated Balloon Angioplasty in the AGENT IDE Trial

Source :: PR Newswire. October 25, 2023
Publication Year :: 2023
Abstract: Data from first coronary DCB study in U.S. meet 12-month primary endpoint, demonstrate low adverse event rates with AGENT DCB MARLBOROUGH, Mass. and SAN FRANCISCO, Oct. 25, 2023 /PRNewswire/ -- [...]

Subjects :: Boston Scientific Corp. -- Product development
Medical research
Medicine, Experimental
Stent (Surgery) -- Product development
Medical test kit industry -- Product development
Medical equipment and supplies industry -- Product development
Transluminal angioplasty
Business
News, opinion and commentary

Tools